Mark Ebbert

5.5k total citations · 2 hit papers
55 papers, 2.7k citations indexed

About

Mark Ebbert is a scholar working on Molecular Biology, Genetics and Physiology. According to data from OpenAlex, Mark Ebbert has authored 55 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 13 papers in Genetics and 10 papers in Physiology. Recurrent topics in Mark Ebbert's work include Alzheimer's disease research and treatments (9 papers), Bioinformatics and Genomic Networks (7 papers) and Breast Cancer Treatment Studies (7 papers). Mark Ebbert is often cited by papers focused on Alzheimer's disease research and treatments (9 papers), Bioinformatics and Genomic Networks (7 papers) and Breast Cancer Treatment Studies (7 papers). Mark Ebbert collaborates with scholars based in United States, Canada and Czechia. Mark Ebbert's co-authors include Philip S. Bernard, Inge J. Stijleman, Perry G. Ridge, Bryan E. Welm, Rachel E. Factor, Cindy Matsen, Saundra S. Buys, Yoko S. DeRose, Brett Milash and R. Lor Randall and has published in prestigious journals such as Nature Medicine, Nature Genetics and The Journal of Experimental Medicine.

In The Last Decade

Mark Ebbert

54 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

2011 699 citations Philip S. Bernard, Mark Ebbert et al. profile →
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

2010 542 citations Torsten O. Nielsen, Joel S. Parker et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Mark Ebbert

Since Specialization

Citations

This map shows the geographic impact of Mark Ebbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Ebbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Ebbert more than expected).

Fields of papers citing papers by Mark Ebbert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Ebbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Ebbert. The network helps show where Mark Ebbert may publish in the future.

Co-authorship network of co-authors of Mark Ebbert

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Ebbert. A scholar is included among the top collaborators of Mark Ebbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Ebbert. Mark Ebbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A bioinformatic survey of RNA isoform diversity and expression across 9 GTEx tissues using long-read sequencing data 2025 ·BMC Genomics ·(unknown), (unknown), J. Anthony Brandon, Mark E. Wadsworth, (unknown), (unknown), David W. Fardo, Mark Ebbert	1
2	Systematic review and meta‐analysis of bulk RNAseq studies in human Alzheimer's disease brain tissue 2025 ·Alzheimer s & Dementia ·(unknown), Kevin Fox, (unknown), (unknown), (unknown), (unknown), David W. Fardo, Thiago Wendt Viola, Mark Ebbert	4
3	Ramp Sequence May Explain Synonymous Variant Association with Alzheimer’s Disease in the Paired Immunoglobulin-like Type 2 Receptor Alpha (PILRA) 2025 ·Biomedicines ·Justin Miller, J. Anthony Brandon, (unknown), (unknown), (unknown), (unknown), (unknown), Samuel Payne, Mark Ebbert, John S. K. Kauwe, Perry G. Ridge	2
4	Targeted long-read sequencing to quantify methylation of the C9orf72 repeat expansion 2024 ·Molecular Neurodegeneration ·(unknown), NiCole A. Finch, Mariely DeJesus‐Hernandez, Jazmyne L. Jackson, Matthew Baker, (unknown), Eric D. Wieben, Mark Ebbert, Jaimin Shah, Leonard Petrucelli, Rosa Rademakers, Björn Oskarsson, Marka van Blitterswijk	4
5	GWAS of multiple neuropathology endophenotypes identifies new risk loci and provides insights into the genetic risk of dementia 2024 ·Nature Genetics ·Lincoln M. P. Shade, Yuriko Katsumata, Erin L. Abner, (unknown), Steven A. Claas, (unknown), (unknown), J. Anthony Brandon, (unknown), Timothy J. Hohman, Shubhabrata Mukherjee, Richard Mayeux, (unknown), (unknown), Jonathan L. Haines, Walter A. Kukull, Kwangsik Nho, Andrew J. Saykin, (unknown), Julie A. Schneider, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mark Ebbert, Peter T. Nelson, (unknown)	11
6	Profiles of mathematical deficits in children with dyslexia 2024 ·npj Science of Learning ·Bettina Pedemonte, (unknown), Valentina Borghesani, Mark Ebbert, Isabel Elaine Allen, Pedro Pinheiro‐Chagas, (unknown), Zachary Miller, Boon Lead Tee, Maria Luisa Gorno‐Tempini	3
7	Culture shock: microglial heterogeneity, activation, and disrupted single-cell microglial networks in vitro 2022 ·Molecular Neurodegeneration ·(unknown), Tanner Jensen, Jonathon Sens, Kuixi Zhu, Won‐Min Song, Bin Zhang, Mark Ebbert, Rui Chang, John Denis Fryer	49
8	Pairwise Correlation Analysis of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Dataset Reveals Significant Feature Correlation 2021 ·Genes ·(unknown), (unknown), (unknown), (unknown), (unknown), Mark Ebbert, John S. K. Kauwe, (unknown), (unknown)	8
9	Common DNA Variants Accurately Rank an Individual of Extreme Height 2018 ·International Journal of Genomics ·(unknown), Mark Ebbert, R.H. Miller, Meganne Ferrel, Jo Ann T. Tschanz, Christopher Corcoran, Alzheimer’s Disease Neuroimaging Initiative, Perry G. Ridge, John S. K. Kauwe	38
10	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype 2018 ·Acta Neuropathologica ·Shunsuke Koga, Naomi Kouri, Ronald L. Walton, Mark Ebbert, Keith A. Josephs, Irene Litvan, Neill R. Graff‐Radford, J. Eric Ahlskog, Ryan J. Uitti, Jay A. van Gerpen, Bradley F. Boeve, Adam Parks, Owen A. Ross, Dennis W. Dickson	54
11	Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau 2018 ·The Journal of Experimental Medicine ·Silvia S. Kang, Mark Ebbert, (unknown), Casey Cook, Xuewei Wang, Jonathon Sens, (unknown), Leonard Petrucelli, John Denis Fryer	164
12	Conserved DNA methylation combined with differential frontal cortex and cerebellar expression distinguishes C9orf72-associated and sporadic ALS, and implicates SERPINA1 in disease 2017 ·Acta Neuropathologica ·Mark Ebbert, Christian Roß, Luc Pregent, (unknown), Cheng Zhang, Rebecca B. Katzman, Karen Jansen‐West, Yuping Song, Edroaldo Lummertz da Rocha, (unknown), Pamela Desaro, A. Robertson, (unknown), Dennis W. Dickson, Khrista Boylan, Rosa Rademakers, Tamás Ördög, Hu Li, Véronique Belzil	28
13	A novel approach for multi-SNP GWAS and its application in Alzheimer’s disease 2016 ·BMC Bioinformatics ·(unknown), Paul Bodily, Mao Fujimoto, Justin T. Page, Mark Clement, Mark Ebbert, Perry G. Ridge	12
14	Presenilin E318G variant and Alzheimer’s disease risk: the Cache County study 2016 ·BMC Genomics ·(unknown), Mark Ebbert, Maria C. Norton, JoAnn T. Tschanz, Ronald G. Munger, Christopher Corcoran, John Kauwe	10
15	Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk 2015 ·Alzheimer s & Dementia ·Mark Ebbert, Kevin L. Boehme, Mark E. Wadsworth, Lyndsay A. Staley, (unknown), Shubhabrata Mukherjee, Paul K. Crane, Perry G. Ridge, John Kauwe	17
16	Intrinsic Subtypes from PAM50 Gene Expression Assay in a Population-Based Breast Cancer Cohort: Differences by Age, Race, and Tumor Characteristics 2014 ·Cancer Epidemiology Biomarkers & Prevention ·Carol Sweeney, Philip S. Bernard, Rachel E. Factor, Marilyn L. Kwan, Laurel A. Habel, Charles P. Quesenberry, (unknown), Erin Weltzien, Inge J. Stijleman, Carole Davis, Mark Ebbert, Adrienne Castillo, Lawrence H. Kushi, Bette J. Caan	94
17	Population-based analysis of cholesteryl ester transfer protein identifies association between I405V and cognitive decline: the Cache County Study 2014 ·Neurobiology of Aging ·(unknown), (unknown), Michael R. Peterson, (unknown), (unknown), Mark Ebbert, Perry G. Ridge, Maria C. Norton, JoAnn T. Tschanz, Ronald G. Munger, Christopher Corcoran, John Kauwe	9
18	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial 2012 ·Clinical Cancer Research ·Maggie C.U. Cheang, K. David Voduc, Dongsheng Tu, Shan Jiang, Samuel Leung, Stephen Chia, Lois E. Shepherd, Mark N. Levine, Kathleen I. Pritchard, Sherri R. Davies, Inge J. Stijleman, Carole Davis, Mark Ebbert, Joel S. Parker, Matthew J. Ellis, Philip S. Bernard, Charles M. Perou, Torsten O. Nielsen	105
19	A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer breakdown → 2010 ·Clinical Cancer Research ·Torsten O. Nielsen, Joel S. Parker, Samuel Leung, D. Voduc, Mark Ebbert, Tammi L. Vickery, Sherri R. Davies, Jacqueline Snider, Inge J. Stijleman, Jerry P. Reed, Maggie C.U. Cheang, Elaine R. Mardis, Charles M. Perou, Philip S. Bernard, Matthew J. Ellis	542
20	Evolutionary Pressure on Mitochondrial Cytochrome b Is Consistent with a Role of CytbI7T Affecting Longevity during Caloric Restriction 2009 ·PLoS ONE ·(unknown), Mark Ebbert, Mark J. Rowe, David A. McClellan	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact